RÉSUMÉ
BACKGROUND: The role of cytomegalovirus infection as an opportunistic pathogen in exacerbating ulcerative colitis and its response to treatment remain a topic of ongoing debate. Clinicians encounter numerous challenges, including the criteria for differentiating between an acute ulcerative colitis flare and true cytomegalovirus colitis, the diagnostic tests for identifying cytomegalovirus colitis, and determining the appropriate timing for initiating antiviral therapy. CASE PRESENTATION: A 28-year-old Syrian female with a seven-year history of pancolitis presented with worsening bloody diarrhea, abdominal pain, and tenesmus despite ongoing treatment with azathioprine, mesalazine, and prednisolone. She experienced a new flare of acute severe ulcerative colitis despite recently completing two induction doses of infliximab (5 mg/kg) initiated four weeks prior for moderate-to-severe ulcerative colitis. She had no prior surgical history. Her symptoms included watery, bloody diarrhea occurring nine to ten times per day, abdominal pain, and tenesmus. Initial laboratory tests indicated anemia, leukocytosis, elevated C-reactive protein (CRP) and fecal calprotectin levels, and positive CMV IgG. Stool cultures, Clostridium difficile toxin, testing for Escherichia coli and Cryptosporidium, and microscopy for ova and parasites were all negative. Sigmoidoscopy revealed numerous prominent erythematous area with spontaneous bleeding. Biopsies demonstrated CMV inclusions confirmed by immunohistochemistry, although prior biopsies were negative. We tapered prednisolone and azathioprine and initiated ganciclovir at 5 mg/kg for ten days, followed by valganciclovir at 450 mg twice daily for three weeks. After one month, she showed marked improvement, with CRP and fecal calprotectin levels returning to normal. She scored one point on the partial Mayo score. The third induction dose of infliximab was administered on schedule, and azathioprine was resumed. CONCLUSION: Concurrent cytomegalovirus infection in patients with inflammatory bowel disease presents a significant clinical challenge due to its associated morbidity and mortality. Diagnosing and managing this condition is particularly difficult, especially regarding the initiation or continuation of immunosuppressive therapies.
Sujet(s)
Colite , Infections à cytomégalovirus , Femelle , Humains , Adulte , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/traitement médicamenteux , Colite/virologie , Colite/diagnostic , Colite/complications , Maladies inflammatoires intestinales/complications , Maladies inflammatoires intestinales/diagnostic , Maladies inflammatoires intestinales/traitement médicamenteux , Cytomegalovirus/isolement et purification , Rectocolite hémorragique/complications , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/diagnostic , Antiviraux/usage thérapeutique , BiopsieRÉSUMÉ
Cytomegalovirus (CMV) infection is the main opportunistic infection observed after kidney transplantation. Despite the use of prevention strategies, CMV disease still occurs, especially in high-risk patients (donor seropositive/recipient seronegative). Patients may develop complicated CMV, i.e. recurrent, refractory or resistant CMV infection. CMV prevention relies on either universal prophylaxis or preemptive therapy. In high-risk patients, universal prophylaxis is usually preferred. Currently, valganciclovir is used in this setting. However, valganciclovir can be responsible for severe leucopenia and neutropenia. A novel anti-viral drug, letermovir, has been recently compared to valganciclovir. It was as efficient as valganciclovir to prevent CMV disease and induced less hematological side-effects. It is still not available in France in this indication. Recent studies suggest that immune monitoring by ELISPOT or Quantiferon can be useful to determine the duration of prophylaxis. Other studies suggest that prophylaxis may be skipped in CMV-seropositive kidney-transplant patients given mTOR inhibitors. Refractory CMV is defined by the lack of decrease of CMV DNAemia of at least 1 log10 at 2 weeks after effective treatment. In case of refractory CMV infection, drug resistant mutations should be looked for. Currently, maribavir is the gold standard therapy for refractory/resistant CMV. At 8 weeks therapy and 8 weeks later, it has been shown to be significantly more effective than other anti-viral drugs, i.e. high dose of ganciclovir, foscarnet or cidofovir. However, a high rate of relapse was observed after ceasing therapy. Hence, other therapeutic strategies should be evaluated in order to improve the sustained virological rate.
L'infection à cytomégalovirus (CMV) est la principale infection opportuniste après transplantation rénale. Malgré les stratégies préventives, il persiste des maladies à CMV, notamment chez les patients à haut risque (donneur séropositif/receveur séronégatif). Certains patients présentent des formes complexes avec des récurrences et des infections réfractaires et/ou résistantes aux antiviraux. La prévention de l'infection à CMV repose soit sur une prophylaxie universelle, soit sur une stratégie préemptive. Chez les patients à haut risque, la stratégie prophylactique est le plus souvent utilisée. Elle repose sur l'utilisation du valganciclovir, qui peut être responsable de leucopénies et de neutropénies sévères. Un nouvel antiviral, le létermovir, qui n'est pas encore disponible sur le marché en France dans cette indication, a montré une efficacité similaire au valganciclovir avec peu d'effets secondaires hématologiques. Des études récentes suggèrent l'intérêt de l'immuno-surveillance par ELISPOT ou Quantiféron pour guider la durée de la prophylaxie. D'autres études suggèrent également la possibilité de se passer d'un traitement prophylactique anti-CMV chez des transplantés rénaux CMV-séropositifs recevant des inhibiteurs de la mTOR. Le CMV réfractaire est défini par une absence de baisse de la charge virale d'au moins 1 log10 après deux semaines de traitement efficace. En cas d'absence de baisse de la charge virale, une recherche de mutations de résistance aux antiviraux doit être effectuée. Actuellement, le maribavir constitue le traitement de référence pour les formes réfractaires et résistantes. La clairance virale à la fin du traitement, ou huit semaines plus tard, est significativement supérieure à celle observée avec les autres antiviraux tels que le ganciclovir donné à forte dose, le foscarnet, ou le cidofovir. Cependant, le taux de rechute à l'arrêt du traitement par maribavir reste important. D'autres stratégies thérapeutiques doivent être évaluées pour améliorer ce taux de réponse virologique soutenue.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Transplantation rénale , Humains , Transplantation rénale/effets indésirables , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/prévention et contrôle , Antiviraux/usage thérapeutique , Valganciclovir/usage thérapeutique , Quinazolines/usage thérapeutique , Ganciclovir/usage thérapeutique , Ribonucléosides/usage thérapeutique , Acétates , Dichlororibofuranosylbenzimidazole/analogues et dérivésRÉSUMÉ
Herpesviral protein kinases, such as the therapy-relevant pUL97 of human cytomegalovirus (HCMV), are important for viral replication efficiency as well as pathogenesis, and represent key antiviral drug targets. HCMV pUL97 is a viral cyclin-dependent kinase (CDK) ortholog, as it shares functional and structural properties with human CDKs. Recently, the formation of vCDK/pUL97-cyclin complexes and the phosphorylation of a variety of viral and cellular substrate proteins has been demonstrated. Genetic mapping and structural modeling approaches helped to define two pUL97 interfaces, IF1 and IF2, responsible for cyclin binding. In particular, the regulatory importance of interactions between vCDK/pUL97 and host cyclins as well as CDKs has been highlighted, both as determinants of virus replication and as a novel drug-targeting option. This aspect was substantiated by the finding that virus replication was impaired upon cyclin type H knock-down, and that such host-directed interference also affected viruses resistant to existing therapies. Beyond the formation of binary interactive complexes, a ternary pUL97-cyclin H-CDK7 complex has also been described, and in light of this, an experimental trans-stimulation of CDK7 activity by pUL97 appeared crucial for virus-host coregulation. In accordance with this understanding, several novel antiviral targeting options have emerged. These include kinase inhibitors directed to pUL97, to host CDKs, and to the pUL97-cyclin H interactive complexes. Importantly, a statistically significant drug synergy has recently been reported for antiviral treatment schemes using combinations of pharmacologically relevant CDK7 and vCDK/pUL97 inhibitors, including maribavir. Combined, such findings provide increased options for anti-HCMV control. This review focuses on regulatory interactions of vCDK/pUL97 with the host cyclin-CDK apparatus, and it addresses the functional relevance of these key effector complexes for viral replication and pathogenesis. On this basis, novel strategies of antiviral drug targeting are defined.
Sujet(s)
Antiviraux , Kinases cyclines-dépendantes , Cytomegalovirus , Protéines virales , Humains , Antiviraux/pharmacologie , Cytomegalovirus/effets des médicaments et des substances chimiques , Cytomegalovirus/physiologie , Protéines virales/métabolisme , Protéines virales/composition chimique , Kinases cyclines-dépendantes/métabolisme , Kinases cyclines-dépendantes/antagonistes et inhibiteurs , Réplication virale/effets des médicaments et des substances chimiques , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/virologie , Animaux , Cyclines/métabolisme , Phosphotransferases (Alcohol Group Acceptor)RÉSUMÉ
To explore the impacts of cytomegalovirus (CMV) infection and antiviral treatment (AVT) on native liver survival (NLS) in biliary atresia (BA) infants. This retrospective cohort study included infants diagnosed as BA between January 2015 and December 2021 at Hunan Children's Hospital. CMV infection was defined by DNA polymerase chain reaction alone (DNA data set) and combination of DNA and immunoglobulin M (CMV data set). In the DNA data set of 330 patients, 234 patients (70.9%) survived with their native liver in 2 years, with 113 (73.9%) in the DNA- cohort, 70 (65.4%) in the DNA+ and AVT- cohort and 51 (72.9%) in the DNA+ and AVT+ cohort, without significant differences by log-rank tests. In patients administrated between 2015 and March 2019, there were 206 evaluable patients in the DNA data set, with rates of 5-year NLS of 68.3% in the DNA- cohort, similar to that in the DNA+ and AVT+ cohort (62.2%, p = 0.546), but significantly higher than that in the DNA+ and AVT- cohort (51.4%, p = 0.031). Similar trends were also observed in the CMV data set, although statistically insignificant. CMV infection before or on the day of HPE can reduce the rate of 5-year NLS and AVT was recommended for CMV-infected BA infants.
Sujet(s)
Antiviraux , Atrésie des voies biliaires , Infections à cytomégalovirus , Cytomegalovirus , Humains , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/virologie , Études rétrospectives , Atrésie des voies biliaires/traitement médicamenteux , Antiviraux/usage thérapeutique , Femelle , Mâle , Nourrisson , Cytomegalovirus/génétique , Cytomegalovirus/effets des médicaments et des substances chimiques , Pronostic , ADN viral , Nouveau-néSujet(s)
COVID-19 , Herpès , Humains , COVID-19/complications , COVID-19/thérapie , Herpès/traitement médicamenteux , Herpès/complications , Antiviraux/usage thérapeutique , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/complications , SARS-CoV-2 , Poumon/physiopathologie , Cytomegalovirus , Simplexvirus/pathogénicité , Activation viraleSujet(s)
Antiviraux , Infections à cytomégalovirus , Cytomegalovirus , Association de médicaments , Transplantation rénale , Récidive , Humains , Transplantation rénale/effets indésirables , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/virologie , Antiviraux/usage thérapeutique , Cytomegalovirus/effets des médicaments et des substances chimiques , Cytomegalovirus/isolement et purification , Mâle , Adulte d'âge moyen , Ganciclovir/usage thérapeutique , Receveurs de transplantation , Résultat thérapeutique , Immunosuppresseurs/usage thérapeutique , Femelle , Résistance virale aux médicamentsRÉSUMÉ
Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge and are associated with increased morbidity and mortality. Novel anti-CMV therapies have been recently developed and introduced in clinical practice, which may improve the treatment of these infections. In this review, we summarize the treatment options for R/R CMV infections in adult hematopoietic cell transplant and solid organ transplant recipients, with a special focus on newly available antiviral agents with anti-CMV activity, including maribavir and letermovir.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Cytomegalovirus , Résistance virale aux médicaments , Receveurs de transplantation , Humains , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/étiologie , Antiviraux/usage thérapeutique , Cytomegalovirus/effets des médicaments et des substances chimiques , Cytomegalovirus/physiologie , Transplantation de cellules souches hématopoïétiques/effets indésirables , Transplantation d'organe/effets indésirables , Acétates , Dichlororibofuranosylbenzimidazole/analogues et dérivés , QuinazolinesRÉSUMÉ
Cytomegalovirus (CMV) infection is a significant clinical concern in newborns, immunocompromised patients with acquired immunodeficiency syndrome (AIDS), and patients undergoing immunosuppressive therapy or chemotherapy. CMV infection affects many organs, such as the lungs, digestive organs, the central nerve system, and eyes. In addition, CMV infection sometimes occurs in immunocompetent individuals. CMV ocular diseases includes retinitis, corneal endotheliitis, and iridocyclitis. CMV retinitis often develops in infected newborns and immunocompromised patients. CMV corneal endotheliitis and iridocyclitis sometimes develop in immunocompetent individuals. Systemic infections and CMV ocular diseases often require systemic treatment in addition to topical treatment.
Sujet(s)
Infections à cytomégalovirus , Cytomegalovirus , Iridocyclite , Humains , Iridocyclite/virologie , Iridocyclite/traitement médicamenteux , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/complications , Rétinite à cytomégalovirus/traitement médicamenteux , Rétinite à cytomégalovirus/virologie , Antiviraux/usage thérapeutique , Endothélium de la cornée/virologie , Endothélium de la cornée/anatomopathologie , Infections virales de l'oeil/virologie , Infections virales de l'oeil/traitement médicamenteux , Sujet immunodéprimé , Kératite/virologie , Kératite/traitement médicamenteuxRÉSUMÉ
This retrospective cohort study investigated patients with cytomegalovirus anterior uveitis (CMV AU) and compared treatment outcomes between regional and systemic antiviral therapies. Treatment modalities included topical (2% ganciclovir [GCV] eye drops or 0.2% GCV eye gel) and systemic (intravenous GCV or oral valganciclovir) groups. The comparison parameters included response rates, time to response, recurrence rates, time to recurrence, and complications. Forty-four patients (54.5% male) with a mean age of 56 ± 9.87 years were enrolled, with 31 eyes in the topical group and 13 eyes in the systemic group. The median response time was significantly slower in the topical group (63 days [IQR 28-112]) compared to the systemic group (28 days [IQR 24-59]) (p = 0.04). Treatment response rates were 87.1% (27/31) in the topical group and 100% (13/13) in the systemic group (p = 0.30), while recurrence rates were 37% (10/27) and 69.2% (9/13) (p = 0.056), with a median time to recurrence of 483 days [IQR 145-1388] and 392 days [IQR 203.5-1907.5] (p = 0.20), respectively. In conclusion, both topical and systemic GCV treatments demonstrated favorable outcomes for CMV AU. Systemic GCV showed rapid control of intraocular inflammation.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Ganciclovir , Uvéite antérieure , Humains , Mâle , Femelle , Adulte d'âge moyen , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/virologie , Uvéite antérieure/traitement médicamenteux , Uvéite antérieure/virologie , Antiviraux/usage thérapeutique , Antiviraux/administration et posologie , Études rétrospectives , Résultat thérapeutique , Ganciclovir/usage thérapeutique , Ganciclovir/administration et posologie , Sujet âgé , Cytomegalovirus , Adulte , Valganciclovir/usage thérapeutique , Récidive , Solutions ophtalmiquesRÉSUMÉ
We present a challenging clinical case of a 68-year-old female kidney transplant recipient who had a complicated posttransplant course marked by borderline T-cell-mediated rejection and BK virus nephropathy. The treatment for borderline rejection with steroids resulted in overimmunosuppression, and the patient acquired cytomegalovirus infection manifesting as colitis and SARS-CoV-2 infection. This progressed rapidly to collapsing glomerulopathy and allograft failure. This study also highlights the challenges in surveillance with donor-derived cell-free DNA in the setting of allograft injury by multiple viral infections.
Sujet(s)
Virus BK , COVID-19 , Infections à cytomégalovirus , Rejet du greffon , Transplantation rénale , Infections à polyomavirus , Infections à virus oncogènes , Humains , Femelle , COVID-19/complications , COVID-19/immunologie , COVID-19/diagnostic , Sujet âgé , Transplantation rénale/effets indésirables , Infections à polyomavirus/immunologie , Infections à polyomavirus/virologie , Infections à polyomavirus/diagnostic , Infections à cytomégalovirus/immunologie , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/traitement médicamenteux , Rejet du greffon/immunologie , Rejet du greffon/virologie , Virus BK/pathogénicité , Virus BK/immunologie , Infections à virus oncogènes/immunologie , Infections à virus oncogènes/virologie , Infections à virus oncogènes/diagnostic , Évolution de la maladie , Résultat thérapeutique , Immunosuppresseurs/effets indésirables , Immunosuppresseurs/usage thérapeutique , Co-infectionRÉSUMÉ
BACKGROUND: Hemorrhagic varicella (HV) is a particular form of chicken pox.,with high mortality in adults. This form of the disease is rare, to date, approximately 4 cases have been reported. Occasional cases of HV have been documented in adults with hematologic disorders or other diseases. While there is one reported case of simultaneous reactivation of cytomegalovirus in an adult with chickenpox, there is a lack of information regarding changes in liver function indicators for such patients. This is unfortunate, as CMV reactivation can further exacerbate liver failure and increase mortality. In this report, we present a case of hemorrhagic varicella reactivation with cytomegalovirus and provide some relevant discussions. CASE PRESENTATION: We present the case of a 25-year-old male with HV, who had a history of nephrotic syndrome generally controlled with orally administered prednisone at a dosage of 50 mg per day for two months. The patient arrived at the emergency room with complaints of abdominal pain and the presence of hemorrhagic vesicles on his body for the past 3 days. Despite medical evaluation, a clear diagnosis was not immediately determined. Upon admission, the leukocyte count was recorded as 20.96 × 109/L on the first day, leading to the initiation of broad-spectrum antibiotic treatment. Despite the general interpretation that a positive IgG and a negative IgM indicate a previous infection, the patient's extraordinarily elevated IgG levels, coupled with a markedly increased CMV DNA quantification, prompted us to suspect a reactivation of the CMV virus. In light of these findings, we opted for the intravenous administration of ganciclovir as part of the treatment strategy. Unfortunately,,the patient succumbed to rapidly worsening symptoms and passed away. Within one week of the patient's demise, chickenpox gradually developed in the medical staff who had been in contact with him. In such instances, we speculate that the patient's diagnosis should be classified as a rare case of hemorrhagic varicella. CONCLUSION: Swift identification and timely administration of suitable treatment for adult HV are imperative to enhance prognosis.
Sujet(s)
Varicelle , Co-infection , Infections à cytomégalovirus , Cytomegalovirus , Humains , Mâle , Adulte , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/diagnostic , Cytomegalovirus/isolement et purification , Varicelle/traitement médicamenteux , Varicelle/complications , Varicelle/virologie , Varicelle/diagnostic , Co-infection/virologie , Co-infection/traitement médicamenteux , Antiviraux/usage thérapeutique , Antiviraux/administration et posologie , Hémorragie/virologie , Hémorragie/étiologie , Herpèsvirus humain de type 3/isolement et purification , Activation viraleRÉSUMÉ
BACKGROUND: Viral reactivations are frequent in hematologial patients due to their cancer-related and drug-induced immunosuppressive status. Daratumumab, an anti-CD38 monoclonal antibody, is used for multiple myeloma (MM) treatment, and causes immunosuppression by targeting CD38-expressing normal lymphocytes. In this single-center two-arm real-life experience, we evaluated incidence of cytomegalovirus (CMV) reactivation in MM patients treated with daratumumab-based regimens as first- or second-line therapy. METHODS: A total of 101 consecutive MM patients were included in this study and were divided into two cohorts: daratumumab and nondaratumumab-based (control) regimens. Patients treated with >2 lines of therapies were excluded to reduce the confounding factor of multi-treated cases. Primary endpoint was the CMV reactivation rate. RESULTS: CMV reactivation rate was significantly higher in the daratumumab cohort compared to control group (33% vs. 4%; p < 0.001), also with higher CMV-DNA levels (>1000 UI/mL in 12% of cases; p < 0.05). However, only one subject developed a CMV disease with severe pneumonia, while 12% of patients were successfully treated with preemptive therapy with valganciclovir. No subjects in the control cohort required anti-CMV agents (p = 0.02). CONCLUSION: Our single-center retrospective experience showed that daratumumab might significantly increase the risk of CMV reactivation in MM, while currently underestimated and related to morbility and mortality in MM patients under treatments. However, further validation on larger and prospective clinical trials are required.
Sujet(s)
Anticorps monoclonaux , Infections à cytomégalovirus , Cytomegalovirus , Myélome multiple , Activation virale , Humains , Myélome multiple/traitement médicamenteux , Mâle , Femelle , Activation virale/effets des médicaments et des substances chimiques , Sujet âgé , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/traitement médicamenteux , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux/effets indésirables , Cytomegalovirus/physiologie , Adulte d'âge moyen , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Études rétrospectives , Valganciclovir/usage thérapeutique , Sujet âgé de 80 ans ou plus , Antiviraux/usage thérapeutiqueRÉSUMÉ
Preemptive therapy (PET) historically has been the primary strategy to reduce early-onset cytomegalovirus (CMV) reactivation after allogeneic hematopoietic cell transplantation (HCT) but is associated with antiviral-associated toxicities and increases in healthcare resource utilization and cost. Despite its high cost, letermovir (LTV) prophylaxis has largely supplanted PET due to its effectiveness and tolerability. Direct comparisons between LTV and PET approaches on economic and clinical outcomes after allogeneic HCT remain limited. Objective: To compare total cost of care (inpatient and outpatient) between LTV prophylaxis and PET through day+180 after allogeneic HCT. Adult allogeneic CMV seropositive (R+) HCT recipients who initiated LTV <30 days after HCT between 01/01/18 and 12/31/18 were matched 1:1 to allogeneic CMV R+ HCT recipients between 01/01/15 and 12/31/17 (PET cohort). Patients were grouped into high-risk (HR) or standard-risk (SR) for CMV to compare the LTV and PET cohorts. Direct costs for each patient's index HCT admission and all subsequent inpatient and outpatient care through day+180 after HCT were determined and converted into 2021 US dollars and then to Medicare proportional dollars (MPD). A secondary analysis using 2019 average wholesale price was conducted to specifically evaluate anti-CMV medication costs. There were a total of 176 patients with 54 HR CMV pairs and 34 SR CMV pairs. No differences in survival between LTV and PET for both HR and SR CMV groups were observed. The rate of clinically significant CMV infection decreased for both HR CMV (11/54, 20.4% versus 38/54, 70.4%, P < .001) and SR CMV (1/34, 2.9% versus 12/34, 35.3%, P < .001) patients who were given LTV prophylaxis with corresponding reductions in val(ganciclovir) and foscarnet (HR CMV only) use. Among HR CMV patients, LTV prophylaxis was associated with reductions in CMV-related readmissions (3/54, 5.6% versus 18/54, 33.3%, P < .001) and outpatient visits within the first 100 days after HCT (20 versus 25, P = .002), and a decreased median total cost of care ($36,018 versus $75,525, P < .001) in MPD was observed. For SR CMV patients on LTV, a significant reduction in the median inpatient cost ($15,668 versus $27,818, P < .001) was found, but this finding was offset by a higher median outpatient cost ($26,145 versus $20,307, P = .030) that was not CMV-driven. LTV prophylaxis is highly effective in reducing clinically significant CMV reactivations for both HR and SR HCT recipients. In this study, LTV prophylaxis was associated with a decreased total cost of care for HR CMV patients through day+180. Specifically, reductions in CMV-related readmissions, exposure to CMV-directed antiviral agents, and outpatient visits in the first 100 days after HCT were observed. SR CMV patients receiving LTV prophylaxis benefited by having a reduced inpatient cost of care due to lowered room and pharmacy costs.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Cytomegalovirus , Transplantation de cellules souches hématopoïétiques , Quinazolines , Humains , Transplantation de cellules souches hématopoïétiques/effets indésirables , Transplantation de cellules souches hématopoïétiques/économie , Antiviraux/économie , Antiviraux/usage thérapeutique , Infections à cytomégalovirus/prévention et contrôle , Infections à cytomégalovirus/économie , Infections à cytomégalovirus/traitement médicamenteux , Mâle , Femelle , Quinazolines/usage thérapeutique , Quinazolines/économie , Adulte d'âge moyen , Adulte , Cytomegalovirus/effets des médicaments et des substances chimiques , Acétates/usage thérapeutique , Acétates/économie , Acétates/administration et posologie , Sujet âgé , Résultat thérapeutique , Études rétrospectives , Coûts des soins de santé/statistiques et données numériques , Analyse coût-bénéficeRÉSUMÉ
BACKGROUND: Both humoral and cell-mediated immunity of the patient affected by multiple myeloma (MM) are impaired; thus, infection is the main cause of the onset of symptoms and death caused by MM. Bortezomib is a first-line drug approved for patients with multiple myeloma (MM) and has significantly increased their overall survival. However, bortezomib-induced peripheral neuropathy (PN) remains a significant side effect that has led to its discontinuation in some patients. Guillain-Barre syndrome (GBS) is thought to be related to immune damage, and most patients have cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma infection before onset. Cases of GBS secondary to MM are rare. METHODS: We provide a case of GBS caused by cytomegalovirus infection after MM treatment, and briefly review the existing literature. RESULTS: Secondary GBS after MM. This patient received active treatment. The clinical symptoms are gradually improving. CONCLUSIONS: The use of bortezomib has the risk of reactivating the virus. It is more about the reactivation of hep-atitis B virus. Nonetheless, cytomegalovirus and Epstein-Barr virus shall have our attention. Patients with MM need to monitor CMV, regularly, especially during the treatment of bortezomib. At the same time, they also need to closely monitor the symptoms and signs of the nervous system to guard against the occurrence of GBS.
Sujet(s)
Bortézomib , Infections à cytomégalovirus , Syndrome de Guillain-Barré , Myélome multiple , Femelle , Humains , Adulte d'âge moyen , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Bortézomib/usage thérapeutique , Bortézomib/effets indésirables , Cytomegalovirus/immunologie , Cytomegalovirus/effets des médicaments et des substances chimiques , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/virologie , Syndrome de Guillain-Barré/diagnostic , Syndrome de Guillain-Barré/traitement médicamenteux , Syndrome de Guillain-Barré/étiologie , Myélome multiple/traitement médicamenteux , Myélome multiple/complicationsRÉSUMÉ
BACKGROUND: Kidney transplant recipients are vulnerable to infections, especially cytomegalovirus (CMV) disease. It is recommended that clinicians plan their prophylaxis and therapeutic regimens based on viral load testing. OBJECTIVE: CMV viral load monitoring testing provides useful information for identifying virologic response and possible antiviral resistance. Due to the paucity of medical literature on guiding viral therapy in cases of CMV tissue disease with nondetectable serum viral load, we intend to provide physicians with evidence on how to guide medical therapy in these cases. CASE REPORT: A 49-year-old Hispanic male recipient of a kidney transplant from a cadaver donor presented to the emergency department with anorexia, asthenia, diarrhea, weight loss, and supraclavicular and mediastinal adenomegalies at 2 months post-transplantation. Both patients were serum IgG- and IgM-positive for CMV, which classified them as intermediate risk for developing CMV disease or tissue-invasive disease (donor-positive/recipient-positive [D+/R+]). The patient was induced with basiliximab and methylprednisolone and received maintenance therapy with tacrolimus, mycophenolic acid, and prednisone. Real-time polymerase chain reaction analyses were performed due to suspicion for BK virus, B19 parvovirus, Epstein-Barr virus, and CMV, with an undetectable viral load for all. A biopsy specimen taken from the gastrointestinal tract confirmed CMV infection, which was corroborated through immunocytochemistry. CONCLUSIONS: Histopathologic testing is a possible option for patients with CMV tissue disease symptoms but no detectable serum viral load. Clinical observation is fundamental when viral monitoring is difficult.
Sujet(s)
Infections à cytomégalovirus , Transplantation rénale , Charge virale , Humains , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/virologie , Mâle , Adulte d'âge moyen , Transplantation rénale/effets indésirables , Immunosuppresseurs/usage thérapeutique , Cytomegalovirus/génétique , Maladies gastro-intestinales/virologieRÉSUMÉ
Emergence of drug resistance is rare after use of letermovir (LMV) as prophylaxis for post-transplant cytomegalovirus (CMV) infection. In a recent study involving renal transplant recipients, no known LMV resistance mutations were detected in those receiving LMV prophylaxis. However, uncharacterized viral amino acid substitutions were detected in LMV recipients by deep sequencing in viral subpopulations of 5%-7%, at codons previously associated with drug resistance: UL56 S229Y (n = 1), UL56 M329I (n = 9) and UL89 D344Y (n = 5). Phenotypic analysis of these mutations in a cloned laboratory CMV strain showed that S229Y conferred a 2-fold increase in LMV EC50, M329I conferred no LMV resistance, and D344Y knocked out viral viability that was restored after the nonviable clone was reverted to wild type D344. As in previous CMV antiviral trials, the detection of nonviable mutations, even in multiple study subjects, raises strong suspicion of genotyping artifacts and encourages the use of replicate testing for authentication of atypical mutation readouts. The non-viability of UL89 D344Y also confirms the biologically important locus of the D344E substitution that confers resistance to benzimidazole CMV terminase complex inhibitors, but does not feature prominently in LMV resistance.
Sujet(s)
Acétates , Antiviraux , Infections à cytomégalovirus , Cytomegalovirus , Résistance virale aux médicaments , Génotype , Phénotype , Quinazolines , Humains , Cytomegalovirus/génétique , Cytomegalovirus/effets des médicaments et des substances chimiques , Antiviraux/pharmacologie , Antiviraux/usage thérapeutique , Résistance virale aux médicaments/génétique , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/traitement médicamenteux , Quinazolines/pharmacologie , Quinazolines/usage thérapeutique , Acétates/pharmacologie , Acétates/usage thérapeutique , Substitution d'acide aminé , Transplantation rénale , Mutation , Variation génétique , Techniques de génotypage/méthodes , Protéines virales/génétiqueRÉSUMÉ
BACKGROUNDS: In critically ill patients with COVID-19, secondary infections are potentially life-threatening complications. This study aimed to determine the prevalence, clinical characteristics, and risk factors of CMV reactivation among critically ill immunocompetent patients with COVID-19 pneumonia. METHODS: A retrospective cohort study was conducted among adult patients who were admitted to ICU and screened for quantitative real-time PCR for CMV viral load in a tertiary-care hospital during the third wave of the COVID-19 outbreak in Thailand. Cox regression models were used to identify significant risk factors for developing CMV reactivation. RESULTS: A total of 185 patients were studied; 133 patients (71.9%) in the non-CMV group and 52 patients (28.1%) in the CMV group. Of all, the mean age was 64.7±13.3 years and 101 patients (54.6%) were males. The CMV group had received a significantly higher median cumulative dose of corticosteroids than the non-CMV group (301 vs 177 mg of dexamethasone, p<0.001). Other modalities of treatments for COVID-19 including anti-viral drugs, anti-cytokine drugs and hemoperfusion were not different between the two groups (p>0.05). The 90-day mortality rate for all patients was 29.1%, with a significant difference between the CMV group and the non-CMV group (42.3% vs. 24.1%, p = 0.014). Median length of stay was longer in the CMV group than non-CMV group (43 vs 24 days, p<0.001). The CMV group has detectable CMV DNA load with a median [IQR] of 4,977 [1,365-14,742] IU/mL and 24,570 [3,703-106,642] in plasma and bronchoalveolar fluid, respectively. In multivariate analysis, only a cumulative corticosteroids dose of dexamethasone ≥250 mg (HR = 2.042; 95%CI, 1.130-3.688; p = 0.018) was associated with developing CMV reactivation. CONCLUSION: In critically ill COVID-19 patients, CMV reactivation is frequent and a high cumulative corticosteroids dose is a significant risk factor for CMV reactivation, which is associated with poor outcomes. Further prospective studies are warranted to determine optimal management.
Sujet(s)
COVID-19 , Maladie grave , Infections à cytomégalovirus , Cytomegalovirus , Humains , Mâle , Adulte d'âge moyen , COVID-19/épidémiologie , COVID-19/virologie , COVID-19/complications , Femelle , Infections à cytomégalovirus/épidémiologie , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/complications , Facteurs de risque , Sujet âgé , Cytomegalovirus/physiologie , Cytomegalovirus/effets des médicaments et des substances chimiques , Cytomegalovirus/isolement et purification , Études rétrospectives , Prévalence , SARS-CoV-2/isolement et purification , SARS-CoV-2/physiologie , Activation virale/effets des médicaments et des substances chimiques , Thaïlande/épidémiologie , Charge viraleRÉSUMÉ
The clinical data of five patients [one male and four female; median age: 31 (21-65) years] with cytomegalovirus (CMV)-induced hemophagocytic lymphohistiocytosis (HLH) diagnosed and treated in the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed from January 2011 to December 2020. None of the patients had any underlying disease, and all were immunocompetent. The main clinical presentations were fever in all five patients, splenomegaly in four, enlarged lymph nodes in two, liver enlargement in one, and rash in three. Pulmonary infection was found in three patients, two of whom developed respiratory failure. Two patients had jaundice. Central nervous system symptoms and gastrointestinal bleeding were observed in one case. All patients received glucocorticoids and antiviral therapy. One patient was treated with the COP (cyclophosphamide+vincristine+prednisone) chemotherapy regimen after antiviral therapy failed and he developed central nervous system symptoms. After treatment, four patients achieved remission, but the fifth pregnant patient eventually died of disease progression after delivery. CMV-associated HLH in an immunocompetent individual without underlying diseases is extremely rare, and most patients have favorable prognosis. Antiviral therapy is the cornerstone of CMV-HLH treatment.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/traitement médicamenteux , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/étiologie , Mâle , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/diagnostic , Femelle , Adulte , Études rétrospectives , Adulte d'âge moyen , Antiviraux/usage thérapeutique , Jeune adulte , Sujet âgé , Cytomegalovirus , PronosticRÉSUMÉ
PURPOSE OF REVIEW: Universal and targeted screening of newborns for congenital cytomegalovirus (CMV) infection is increasing globally. Questions remain concerning the management of infants who have been identified with congenital CMV infection, especially those with "minimally symptomatic" or clinically inapparent infection. Our objective is to discuss current management of CMV-infected neonates with a focus on less affected infants with or without sensorineural hearing loss (SNHL). RECENT FINDINGS: Valganciclovir is being prescribed increasingly in neonates with congenital CMV infection for improvement in hearing outcomes through 2 years of age. Treatment initiated in the first month of age is recommended for clinically apparent disease. A recent study showed hearing improvement at 18-22âmonths of age when therapy was initiated at age 1-3 months in infants with clinically inapparent CMV infection and isolated SNHL. SUMMARY: Antiviral therapy with either ganciclovir or valganciclovir has shown moderate benefit in prevention of hearing deterioration among infants with clinically apparent CMV infection or isolated SNHL. Sustainability of benefit beyond 2 years of age remains unknown. At present, infants with clinically inapparent CMV infection (normal complete evaluation including hearing) should not receive antiviral therapy. All CMV-infected infants require close audiological and neurodevelopmental follow-up.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Ganciclovir , Surdité neurosensorielle , Valganciclovir , Humains , Infections à cytomégalovirus/congénital , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/complications , Antiviraux/usage thérapeutique , Surdité neurosensorielle/virologie , Surdité neurosensorielle/diagnostic , Surdité neurosensorielle/étiologie , Nouveau-né , Valganciclovir/usage thérapeutique , Ganciclovir/usage thérapeutique , Ganciclovir/analogues et dérivés , Nourrisson , Dépistage néonatal/méthodesRÉSUMÉ
The tegument protein pp150 of Human Cytomegalovirus (HCMV) is known to be essential for the final stages of virus maturation and mediates its functions by interacting with capsid proteins. Our laboratory has previously identified the critical regions in pp150 important for pp150-capsid interactions and designed peptides similar in sequence to these regions, with a goal to competitively inhibit capsid maturation. Treatment with a specific peptide (PepCR2 or P10) targeted to pp150 conserved region 2 led to a significant reduction in murine CMV (MCMV) growth in cell culture, paving the way for in vivo testing in a mouse model of CMV infection. However, the general pharmacokinetic parameters of peptides, including rapid degradation and limited tissue and cell membrane permeability, pose a challenge to their successful use in vivo. Therefore, we designed a biopolymer-stabilized elastin-like polypeptide (ELP) fusion construct (ELP-P10) to enhance the bioavailability of P10. Antiviral efficacy and cytotoxic effects of ELP-P10 were studied in cell culture, and pharmacokinetics, biodistribution, and antiviral efficacy were studied in a mouse model of CMV infection. ELP-P10 maintained significant antiviral activity in cell culture, and this conjugation significantly enhanced P10 bioavailability in mouse tissues. The fluorescently labeled ELP-P10 accumulated to higher levels in mouse liver and kidneys as compared to the unconjugated P10. Moreover, viral titers from vital organs of MCMV-infected mice indicated a significant reduction of virus load upon ELP-P10 treatment. Therefore, ELP-P10 has the potential to be developed into an effective antiviral against CMV infection.